興科蓉醫藥：2020中期報告.pdf

1、2020 Interim Report 中期報告(Incorporated under the laws of the Cayman Islands with limited liability)(根據開曼群島法例註冊成立的有限公司)Stock Code 股份代號:6833(Incorporated under the laws of the Cayman Islands with limited liability)(根據開曼群島法例註冊成立的有限公司)Stock Code 股份代號:6833Contents目錄2Corporate Information公司資料4Financial Hig

2、hlights財務摘要6Corporate Profile公司簡介7Management Discussion and Analysis管理層討論及分析24Other Information其他資料34Independent Review Report獨立審閱報告36Interim Condensed Consolidated Statement of Profi t or Loss andother Comprehensive Income中期簡明綜合損益及其他全面收益表37Interim Condensed Consolidated Statement of Financial Posit

3、ion中期簡明綜合財務狀況表39Interim Condensed Consolidated Statement of Changes in Equity中期簡明綜合權益變動表40Interim Condensed Consolidated Statement of Cash Flows中期簡明綜合現金流量表42Notes to Interim Condensed Financial Information中期簡明財務資料附註74Definitions釋義2Sinco Pharmaceuticals Holdings Limited Interim Report 2020Corporate I

4、nformation公司資料董事會執行董事黃祥彬先生（主席兼行政總裁）張志傑女士獨立非執行董事劉英傑先生汪晴先生劉文芳先生白志中先生（委任自2020年9月1日起生效）審核委員會劉英傑先生（主席）劉文芳先生汪晴先生白志中先生（委任自2020年9月1日起生效）薪酬委員會汪晴先生（主席）張志傑女士劉文芳先生提名委員會黃祥彬先生（主席）劉文芳先生劉英傑先生內部控制及企業管治委員會劉英傑先生（主席）汪晴先生劉文芳先生白志中先生（委任自2020年9月1日起生效）授權代表黃祥彬先生李菁怡女士聯席公司秘書彭雲璐女士李菁怡女士註冊辦事處PO Box 309Ugland HouseGrand Cayman,KY1

5、-1104Cayman IslandsBOARD OF DIRECTORSExecutive DirectorsMr.Huang Xiangbin(Chairman and Chief Executive Officer)Ms.Zhang ZhijieIndependent Non-executive DirectorsMr.Lau Ying KitMr.Wang QingMr.Liu WenfangMr.Bai Zhizhong(appointed with effect from 1 September 2020)AUDIT COMMITTEEMr.Lau Ying Kit(Chairma

6、n)Mr.Liu WenfangMr.Wang QingMr.Bai Zhizhong(appointed with effect from 1 September 2020)REMUNERATION COMMITTEEMr.Wang Qing(Chairman)Ms.Zhang ZhijieMr.Liu WenfangNOMINATION COMMITTEEMr.Huang Xiangbin(Chairman)Mr.Liu WenfangMr.Lau Ying KitINTERNAL CONTROL AND CORPORATE GOVERNANCE COMMITTEEMr.Lau Ying